SEC Comment Letter 0000000000-23-007720 to GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105) (GYRE)
GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105)
Date: July 20, 2023 · CIK: 0001124105 · Accession: 0000000000-23-007720
AI Filing Summary & Sentiment
File numbers found in text: 000-51173
Letter
United States securities and exchange commission logo July 20, 2023 Nassim Usman, Ph.D. President and Chief Executive Officer Catalyst Biosciences, Inc. 611 Gateway Blvd Suite 120 South San Francisco, CA 94080 Re:Catalyst Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 30, 2023 File No. 000-51173 Dear Nassim Usman: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen B. Thau, Esq.
Show Raw Text
United States securities and exchange commission logo
July 20, 2023
Nassim Usman, Ph.D.
President and Chief Executive Officer
Catalyst Biosciences, Inc.
611 Gateway Blvd
Suite 120
South San Francisco, CA 94080
Re:Catalyst Biosciences, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed March 30, 2023
File No. 000-51173
Dear Nassim Usman:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephen B. Thau, Esq.